Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2023

13-09-2022 | Pancreatic Cancer | Original Article

NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1

Authors: Weilin Mao, Lei Zhang, Yefei Rong, Tiantao Kuang, Dansong Wang, Xuefeng Xu, Wenhui Lou, Jianang Li

Published in: Digestive Diseases and Sciences | Issue 4/2023

Login to get access

Abstract

Purpose

Pancreatic cancer is characterized by a dense desmoplasia stroma, which hinders efficient drug delivery and plays a critical role in tumor progression and metastasis. MLN4924 is a first-in-class NEDD8-activating enzyme inhibitor that exhibits anti-tumor activities toward pancreatic cancer, and given the comprehensive effects that MLN4924 could have, we ask what impact MLN4924 would have on the stroma of pancreatic cancer and its underlying mechanisms.

Methods

Primary pancreatic stellate cells (PSCs) and human HMEC-1 cells were treated with MLN4924 in vitro. The proliferation and extracellular matrix protein levels of PSCs were tested, and their relationship with transcription factor Gli1 in PSCs was investigated. The angiogenic phenotypes of HMEC-1 cells were evaluated using capillary-like tube formation assay, and their relationship with REDD1 in HMEC-1 cells was investigated.

Results

In this study, we found that MLN4924 inhibited the proliferation of pancreatic stellate cells and their secretion of collagen and CXCL-1, and the collagen secretion inhibiting effect of MLN4924 was related with transcription factor Gli1. MLN4924 inhibited multiple angiogenic phenotypes of HMEC-1 cells, and mTOR agonist partially relieved the inhibition of MLN4924 on HEMCs. MLN4924 increased the expression of REDD1 and REDD1 knockdown promoted the angiogenic phenotypes of HMEC-1 cells.

Conclusions

Our study suggests that MLN4924 inhibits both the tumor stroma and angiogenesis in pancreatic cancer, and the inhibition effect is related with Gli1 in pancreatic stellate cells and REDD1 in vascular endothelial cells, respectively.
Literature
1.
2.
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.PubMedCrossRef
3.
4.
5.
6.
Apte M, Park S, Phillips P et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004;29:179–187.PubMedCrossRef
7.
Biffi G, Oni TE, Spielman B et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov 2019;9:282–301.PubMedCrossRef
8.
Hessmann E, Patzak M, Klein L et al. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut 2018;67:497–507.PubMedCrossRef
9.
Yoshida N, Masamune A, Hamada S et al. Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer. Cancer Lett 2017;390:103–114.PubMedCrossRef
10.
Qian D, Lu Z, Xu Q et al. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Cancer Lett 2017;397:43–51.PubMedCrossRef
11.
Rhim AD, Oberstein PE, Thomas DH et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25:735–747.PubMedPubMedCentralCrossRef
12.
Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. Reshaping the tumor stroma for treatment of pancreatic cancer. Gastroenterology 2018;154:820–838.PubMedCrossRef
13.
Park J, Cho J, Song EJ. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res 2020:1–18.
14.
Zhao Y, Morgan MA, Sun Y. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal 2014;21:2383–2400.PubMedPubMedCentralCrossRef
15.
16.
17.
Luo Z, Yu G, Lee HW et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012;72:3360–3371.PubMedCrossRef
18.
Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310–10320.PubMedPubMedCentralCrossRef
19.
Lin S, Shang Z, Li S et al. Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. Oncol Lett 2018;15:2583–2589.PubMed
20.
21.
Bachem MG, Schünemann M, Ramadani M et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005;128:907–921.PubMedCrossRef
22.
Fang Y, Han X, Li J, Kuang T, Lou W. HEATR1 deficiency promotes chemoresistance via upregulating ZNF185 and downregulating SMAD4 in pancreatic cancer. J Oncol 2020;2020.
23.
24.
25.
Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev 2006;20:276–281.PubMedPubMedCentralCrossRef
26.
Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2016;10:301–316.PubMedCrossRef
27.
Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771–780.PubMedCrossRef
28.
Katiyar S, Liu E, Knutzen CA et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase. EMBO Rep 2009;10:866–872.PubMedPubMedCentralCrossRef
29.
Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893–2904.PubMedPubMedCentralCrossRef
30.
Shi C-S, Kuo K-L, Lin W-C et al. Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study. Am J Cancer Res 2020;10:953.PubMedPubMedCentral
31.
Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457–1461.PubMedPubMedCentralCrossRef
32.
Ikenaga N, Ohuchida K, Mizumoto K et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010;139:1041–1051.PubMedCrossRef
33.
Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012;11:1282–1290.PubMedCrossRef
34.
Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer treatment: a new frontier. Ther Adv Gastroenterol 2017;10:168–194.CrossRef
35.
Özdemir BC, Pentcheva-Hoang T, Carstens JL et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25:719–734.PubMedPubMedCentralCrossRef
36.
Huang H, Brekken RA. The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. Cancer Res 2019;79:328–330.PubMedCrossRef
37.
van Mackelenbergh MG, Stroes, CI, Spijker R et al. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel), 2019. 11(5).
38.
39.
Hui C, Angers S. Gli proteins in development and disease. Annu Rev Cell Dev Biol 2011;27:513–537.PubMedCrossRef
40.
Nagai S, Nakamura M, Yanai K et al. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci 2008;99:1377–1384.PubMedCrossRef
41.
Joost S, Almada LL, Rohnalter V et al. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res 2012;72:88–99.PubMedCrossRef
42.
Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011;89:31–39.PubMedCrossRef
43.
44.
Cheng W-L, Wang C-S, Huang Y-H, Tsai M-M, Liang Y, Lin K-H. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011;22:2267–2276.PubMedCrossRef
45.
Wang N, Liu W, Zheng Y et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. Cell Death Dis 2018;9:1–18.
46.
Wang D, Sun H, Wei J, Cen B, DuBois RN. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res 2017;77:3655–3665.PubMedPubMedCentralCrossRef
47.
Monti P, Leone BE, Marchesi F et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63:7451–7461.PubMed
48.
Lu Y, Chen Q, Corey E et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009;26:161–169.PubMedCrossRef
49.
Furukawa S, Soeda S, Kiko Y et al. MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res 2013;33:4785–4790.PubMed
50.
Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat 2018;170:477–486.PubMedPubMedCentralCrossRef
51.
52.
Jin H-O, An S, Lee H-C et al. Hypoxic condition-and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1α and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal 2007;19:1393–1403.PubMedCrossRef
53.
Pinno J, Bongartz H, Klepsch O et al. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner. Cell Signal 2016;28:907–916.PubMedCrossRef
54.
Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 2007;100:79–87.PubMedCrossRef
55.
56.
Öhlund D, Handly-Santana A, Biffi G et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017;214:579–596.PubMedPubMedCentralCrossRef
57.
Tjomsland V, Aasrum M, Christoffersen T, Gladhaug IP. Functional heterogeneity in tumor-derived human pancreatic stellate cells: Differential expression of HGF and implications for mitogenic signaling and migration in pancreatic cancer cells. Oncotarget 2017;8:71672.PubMedPubMedCentralCrossRef
58.
Fujiwara K, Ohuchida K, Mizumoto K et al. CD271+ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells. PloS One 2012;7:e52682.PubMedPubMedCentralCrossRef
59.
Farrow B, Rowley D, Dang T, Berger DH. Characterization of tumor-derived pancreatic stellate cells. J Surg Res 2009;157:96–102.PubMedCrossRef
60.
Hingorani SR, Wang L, Multani AS et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469–483.PubMedCrossRef
Metadata
Title
NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1
Authors
Weilin Mao
Lei Zhang
Yefei Rong
Tiantao Kuang
Dansong Wang
Xuefeng Xu
Wenhui Lou
Jianang Li
Publication date
13-09-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07671-w

Other articles of this Issue 4/2023

Digestive Diseases and Sciences 4/2023 Go to the issue

Original Article

A National Survey of the Infrastructure and Scope of Practice for Gastroenterology Hospitalists

Original Article

Hydrogen Availability Is Dependent on the Actions of Both Hydrogen-Producing and Hydrogen-Consuming Microbes

Original Article

Fecal Microbiome Associated with Both Colon Adenomas and Lifetime Colorectal Cancer Risk

Invited Commentary

Muscle Mass Effect: The Importance of Diagnosing and Treating Sarcopenia in Patients with Advanced Chronic Liver Disease

Original Article

Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Original Article

Clinical Outcomes of Patients with Benign Peptic Ulcer Bleeding After an Emergency Endoscopy Based on Patient Location
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits